Hemang B Panchal1, Ramesh Daggubati2, David Zhao3, Sunil V Rao4, Timir Paul5. 1. Division of Cardiology, Department of Internal Medicine, East Tennessee State University, 329 North State of Franklin Rd, Johnson City, TN, USA. 2. Division of Cardiology, Winthrop University Hospital, 259 First Street, Mineola, NY, 11501, USA. 3. Section on Cardiovascular Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157, USA. 4. Duke University Medical Center, Durham VA Medical Center, 508 Fulton Street (111A), Durham, NC, 27705, USA. 5. Department of Internal Medicine, Cardiovascular Research, East Tennessee State University, 329 North State of Franklin Rd, Johnson City, TN, USA. pault@etsu.edu.
Abstract
PURPOSE OF REVIEW: Patients with stable coronary artery disease (CAD) and a high risk of bleeding are not ideal candidates for a polymer-based drug-eluting stent (DES) because it requires 6-12 months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI). The purpose of this review is to assess the angiographic and clinical outcomes of polymer-free drug-coated stents (PF-DCS) in stable CAD patients with a high bleeding risk. RECENT FINDINGS: Several randomized controlled trials (RCTs) have compared angiographic and clinical outcomes of PF-DCS with bare-metal stents (BMS), permanent polymer (PP)-DES, or biodegradable polymer (BP)-DES. However, none of these studies particularly recruited patients with stable CAD and a high risk of bleeding. Furthermore, there are limited data available on duration of DAPT following PF-DCS placement. PF-DCS has a better efficacy and similar safety as compared with BMS. PF-DCS with dual drug is noninferior to currently available PP-DES. Further RCTs are needed to assess the safety and efficacy of PF-DCS to BP-DES and PP-DES comparing shorter to standard durations of DAPT.
PURPOSE OF REVIEW: Patients with stable coronary artery disease (CAD) and a high risk of bleeding are not ideal candidates for a polymer-based drug-eluting stent (DES) because it requires 6-12 months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI). The purpose of this review is to assess the angiographic and clinical outcomes of polymer-free drug-coated stents (PF-DCS) in stable CAD patients with a high bleeding risk. RECENT FINDINGS: Several randomized controlled trials (RCTs) have compared angiographic and clinical outcomes of PF-DCS with bare-metal stents (BMS), permanent polymer (PP)-DES, or biodegradable polymer (BP)-DES. However, none of these studies particularly recruited patients with stable CAD and a high risk of bleeding. Furthermore, there are limited data available on duration of DAPT following PF-DCS placement. PF-DCS has a better efficacy and similar safety as compared with BMS. PF-DCS with dual drug is noninferior to currently available PP-DES. Further RCTs are needed to assess the safety and efficacy of PF-DCS to BP-DES and PP-DES comparing shorter to standard durations of DAPT.
Authors: Didier Carrié; Jacques Berland; Stefan Verheye; Karl Eugen Hauptmann; Mathias Vrolix; Roberto Violini; Alain Dibie; Sergio Berti; Eric Maupas; David Antoniucci; Joachim Schofer Journal: J Am Coll Cardiol Date: 2012-01-25 Impact factor: 24.094
Authors: Ajay J Kirtane; Anuj Gupta; Srinivas Iyengar; Jeffrey W Moses; Martin B Leon; Robert Applegate; Bruce Brodie; Edward Hannan; Kishore Harjai; Lisette Okkels Jensen; Seung-Jung Park; Raphael Perry; Michael Racz; Francesco Saia; Jack V Tu; Ron Waksman; Alexandra J Lansky; Roxana Mehran; Gregg W Stone Journal: Circulation Date: 2009-06-15 Impact factor: 29.690
Authors: Dean J Kereiakes; Ian T Meredith; Stephan Windecker; R Lee Jobe; Shamir R Mehta; Ian J Sarembock; Robert L Feldman; Bernardo Stein; Christophe Dubois; Timothy Grady; Shigeru Saito; Takeshi Kimura; Thomas Christen; Dominic J Allocco; Keith D Dawkins Journal: Circ Cardiovasc Interv Date: 2015-04 Impact factor: 6.546
Authors: Yoshitaka Shiratori; Clarissa Cola; Salvatore Brugaletta; Luis Alvarez-Contreras; Victoria Martín-Yuste; Bruno García del Blanco; Rafael Ruiz-Salmeron; Jose Díaz; Eduardo Pinar; Vicens Martí; Juan García-Picart; Manel Sabaté Journal: Circ Cardiovasc Interv Date: 2014-05-06 Impact factor: 6.546
Authors: W J van der Giessen; A M Lincoff; R S Schwartz; H M van Beusekom; P W Serruys; D R Holmes; S G Ellis; E J Topol Journal: Circulation Date: 1996-10-01 Impact factor: 29.690